Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice

Konosuke Iwamoto1, Yasuhiro Yoshii, Ken Ikeda

  • 1Department of Neurology, Toho University Omori Medical Center, 6-11-1 Omorinishi, Otaku, Tokyo, Japan.

Insights

Atorvastatin treatment significantly slowed motor neuron degeneration in wobbler mice, delaying motor deficits by over four weeks. This cholesterol drug demonstrated neuroprotective effects, preserving muscle function and reducing motor neuron loss.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Wobbler mice serve as a model for motor neuron diseases.
  • Motor neuron degeneration leads to progressive muscle weakness and atrophy.
  • Identifying therapeutic agents to slow neurodegeneration is crucial.

Purpose of the Study:

  • To investigate the neuroprotective potential of atorvastatin in wobbler mice.
  • To assess the impact of atorvastatin on motor function and neuropathology.

Main Methods:

  • Wobbler mice and littermates received atorvastatin or vehicle for 4-8 weeks.
  • Motor function was assessed via pull-strength and forelimb deformity.
  • Neuropathological and biochemical analyses of muscle and spinal cord were performed.

Main Results:

  • Atorvastatin delayed motor deficit progression by over four weeks.
  • It suppressed denervation atrophy by 30% and maintained muscle choline acetyltransferase activity.
  • Approximately 30% of motor neuron loss was attenuated in atorvastatin-treated mice.

Conclusions:

  • Atorvastatin exhibits significant neuroprotective effects in the wobbler mouse model.
  • The drug mitigates motor neuron degeneration and associated muscle atrophy.
  • Atorvastatin holds promise as a therapeutic intervention for motor neuron diseases.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...